Navigation Links
EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
Date:5/19/2011

ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.  The data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3 - 7, 2011 in Chicago, Illinois.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)-

Gynecologic Cancer Track: Poster SessionFriday, June 3, 2011 – 2:00 p.m. - 6:00 p.m. (CDT) Abstract No.: 5021Title: A Phase 2 Study of ENMD-2076 in platinum-resistant ovarian cancer Poster Board: 10, Location: E450aDiscussion SessionFriday, June 3, 2011 – 5:00 p.m. - 6:00 p.m. (CDT)Location: E354bAbout ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 NxStage Medical, Inc. (NASDAQ: ... products, announced today that the U.S. Food and ... to perform hemodialysis overnight while the patient is ... NxStage,s® System One is the first and only ... indication. Home nocturnal hemodialysis is ...
(Date:12/22/2014)... 2014   TRU-D SmartUVC LLC, producers of ... announced today that the General Services Administration has awarded ...   This newly formed agreement will allow ... government purchasers, including Department of Veteran Affairs and Department ... contacts purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... Hospitals spend more each year on medical devices and ... than they would if purchased in the open-market according ... Manufacturers Association (MDMA).  The study empirically shows that GPOs ... them to receive kickbacks from suppliers, and that they ...
... 6 Ferring Pharmaceuticals Inc. today announced publication ... of LYSTEDA™ (tranexamic acid) tablets for cyclic heavy ... the peer-reviewed journal, Obstetrics & Gynecology . ... reduced menstrual blood loss from baseline, and improved ...
Cached Medicine Technology:GPOs Fail to Provide Hospitals and Patients Health Care Savings 2Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 2Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 4
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... (HealthDay News) -- Overeating is common during the holidays, but ... an expert says. "Don,t arrive at a party hungry. ... know you,ll be attending a party, but deprivation leads to ... at Northern Westchester Hospital in Mount Kisco, N.Y., said in ... during the day and even to have a snack before ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... FT. WASHINGTON, Pa., Aug. 25 The makers of ZYRTEC(R) ... announced the availability of two new allergy solutions to help ... Children,s ZYRTEC(R) PERFECT MEASURE(R) and ZYRTEC(R) Itchy Eye Drops are ... products. The company also announced the launch of AllergyCast, ...
... Health Care (IQWiG) was commissioned by the Federal Joint ... from taking drugs belonging to the selective serotonin and ... 2 of these drugs have been approved as antidepressants ... final report on 18 August. According to this report, ...
... hyperplastic polyps, sessile serrated polyps (also called sessile serrated ... serrated polyps share molecular features with a subgroup of ... can be precursors of cancer through a hyperplastic polyp ... to arise in the proximal colon. Sessile serrated polyps ...
... Most of the duodenal diverticula are diagnosed incidentally ... Only 5% to 10% of patients with duodenal ... 1% of patients require treatment for various complications ... treatments and operations are considered for the rare ...
... , , , ... of the millions of Americans that have sensitive teeth, you know that ... coffee or a bowl of ice cream. This summer, Tom,s of Maine ... benefit of environmentally sensitive packaging and manufacturing. , , ...
... babies at risk for osteoporosis decades later, study finds , ... preterm with a very low birth weight have significantly lower ... term, a Finnish study has found. , The researchers evaluated ... who were born preterm with very low birth weight. , ...
Cached Medicine News:Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 2Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 4Health News:Antidepressants: Benefit of SNRI is proven 2Health News:Antidepressants: Benefit of SNRI is proven 3Health News:Reinterpretation of proximal colon polyps called hyperplastic in 2001 2Health News:Tom's of Maine is Good to Your Sensitive Teeth and the Planet 2Health News:Tom's of Maine is Good to Your Sensitive Teeth and the Planet 3
... most other EMR,systems require you ... is the only,electronic patient charting,solution ... orthopaedic,workflow. Created around,five specific criteria ... clinic,OrthoPad allows you to see,more ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... EMS provides service to companies in many different ... and restaurants.There are no hidden charges at EMS ... and service are among the lowest in the ... of services ranging from MasterCard/Visa processing to Debit ...
Medicine Products: